COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,712 Articles (22,913 medRxiv, 8,799 bioRxiv)

Most recent first Previous |  Page 949: Articles 9481-9490  | Next

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
Ohashi, H., Hishiki, T., Akazawa, D., Kim, K. S., Woo, J., Shionoya, K., Tsuchimoto, K., Iwanami, S., Moriyama, S., Kinoshita, H., Yamada, S., Kuroda, Y., Yamamoto, T., Kishida, N., Watanabe, S., Hasegawa, H., Ebihara, H., Suzuki, T., Maeda, K., Fukushi, S., Takahashi, Y., Iwami, S., Watashi, K.
10.1101/2022.02.27.482147 — Posted: 2022-02-28
An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques
Madden, P. J., Thomas, Y., Blair, R. V., Samer, S., Doyle, M., Midkiff, C. C., Becker, M. E., Arif, M. S., McRaven, M. D., Simons, L. M., Carias, A. M., Martinelli, E., Lorenzo-Redondo, R., Hultquist, J. F., Villinger, F. J., Veazey, R. S., Hope, T. J.
10.1101/2022.02.25.481974 — Posted: 2022-02-28
A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2
Priya, P., Basit, A., Bandyopadhyay, P.
10.1101/2022.02.27.482153 — Posted: 2022-02-28
Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3
Ma, H., Tseng, C.-T. K., Zong, H., Liao, Y., Ke, Y., Tang, H., Wang, L., Wang, Z., He, Y., Chang, Y., Wang, S., Drelich, A., Hsu, J., Tat, V., Yuan, Y., Wu, M., Liu, J., Yue, Y., Xu, W., Zhang, X., Wang, Z., Yang, L., Chen, H., Bian, Y., Zhang, B., Yin, H., Chen, Y., Zhang, E., Zhang, X., Gilly, J., Sun, T., Han, L., Xie, Y., Jiang, H., Zhu, J.
10.1101/2022.02.25.482049 — Posted: 2022-02-28
Drivers of adaptive evolution during chronic SARS-CoV-2 infections
Harari, S., Tahor, M., Rutsinsky, N., Meijer, S., Miller, D., Henig, O., Halutz, O., Levytskyi, K., Ben-Ami, R., Adler, A., Paran, Y., Stern, A.
10.1101/2022.02.17.22270829 — Posted: 2022-02-28
Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
Dorabawila, V., Hoefer, D., Bauer, U. E., Bassett, M., Lutterloh, E., Rosenberg, E.
10.1101/2022.02.25.22271454 — Posted: 2022-02-28 Discussion: Onsite
Genomics of Post-Vaccination SARS-CoV-2 Infections During the Delta Dominated Second Wave of COVID-19 Pandemic, from Mumbai Metropolitan Region (MMR), India
Nilgiriwala, K. S., Kadam, P., Patel, G., Shaikh, A., Mestry, T., Vaswani, S., Sakthivel, S., Poojary, A., Gandhi, B., Rohra, S., Udwadia, Z., Oswal, V., Shah, D., Gomare, M., Sriraman, K., Mistry, N.
10.1101/2022.02.26.22271546 — Posted: 2022-02-27
Factors associated with the decay of anti-SARS-CoV-2 neutralizing antibodies among recipients of an adenoviral vector-based AZD1222 and a whole-virion inactivated (BBV152) vaccine in Chennai, India: a cross-sectional cohort study
Selvavinayagam, S. T., Yong, Y. K., Tan, H. Y., Zhang, Z.-Y., Subramanian, G., Rajeshkumar, M., Vasudevan, K., Jayapal, P., Narayanasamy, K., Ramesh, D., Palani, S., Larsson, M., Esaki Muthu, S., Raju, S.
10.1101/2022.02.26.22271097 — Posted: 2022-02-27
SARS-CoV-2 Exposures of Healthcare Workers from Primary Care, Long-Term Care Facilities and Hospitals: A Nationwide Matched Case-Control Study
Belan, M., Charmet, T., Schaeffer, L., Tubiana, S., Duval, X., Lucet, J.-C., Fontanet, A., Birgand, G., Kerneis, S.
10.1101/2022.02.26.22271545 — Posted: 2022-02-27 Discussion: Onsite
Tracing the trajectories of SARS-CoV-2 variants of concern between December 2020 and September 2021 in the Canary Islands (Spain)
Ciuffreda, L., Gonzalez-Montelongo, R., Alcoba-Florez, J., Garcia-Martinez de Artola, D., Gil-Campesino, H., Rodriguez-Perez, H., Inigo-Campos, A., De Miguel-Martinez, I., Tosco-Nunez, T., Diez-Gil, O., Valenzuela-Fernandez, A., Lorenzo-Salazar, J. M., Flores, C.
10.1101/2022.02.26.22271544 — Posted: 2022-02-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).